Abbvie Inc. vs Summit Therapeutics Inc.
ABBV vs SMMT — side-by-side comparison from reported financials. ABBV leads 4, SMMT leads 1 of 5 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Summit Therapeutics Inc.
SMMT · Healthcare
$17.55+2.21%Strained
| Metric | ABBV | SMMT |
|---|---|---|
| Price | $276.43 | $17.55 |
| Market cap | $488B | $14.0B |
| Revenue (TTM) | $64.4B | — |
| Revenue growth | +1.8% | — |
| Net margin | 9.8% | — |
| Free cash flow | $18.2B | -$932M |
| Net cash (debt) | ($56.2B) | $670M |
| 1-year price return | +19.8% | -22.5% |
| P/E | 77.4 | — |
| P/E vs own history (cheap-side %) | 23% | — |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | -169% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 3 of 11 |
| Employees | 57,000 | 265 |
Full résumé-style profiles: ABBV CV · SMMT CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.